FDA 483 - Lotus Labs Pvt. Ltd.

Lotus Labs Private Limited in Bangalore, India, a Contract Research Organization (CRO), was cited for three significant issues during an FDA inspection. These included performing screening procedures without proper informed consent, failing to adequately follow up on an adverse event until its resolution, and enrolling subjects who met exclusion criteria for clinical studies. The findings indicate deficiencies in clinical trial conduct and subject protection.